BD announced the results of a new survey revealing that 74% of women in Canada have delayed a gynecology visit, with 83% wanting more accessible and less invasive cervical cancer testing options, including at-home self-collection for human papillomavirus (HPV) tests.

BD announced today Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use of self-collected vaginal specimens at home.

Mackenzie Health recently launched BD Alaris™ EMR Bidirectional Interoperability, which allows for two-way information flow between an IV pump and a patient’s electronic medical record.

Humber and BD are working together to reshape the landscape of health care workforce development and address the evolving needs of the industry along with health human resources.

BD-Canada is aware of the U.S. FDA issuing Safety Communication stating concern that certain plastic syringes may not provide consistent and adequate quality or performance.

The kidney care community advocates for more cost-effective treatment options, which offer a better quality of life and improved outcomes, although several obstacles hinder significant progress in improving kidney failure treatment.

Cervical cancer is one of the few cancers that is almost completely preventable through systematic screening programs, early detection with HPV testing and vaccination. Our generation holds the incredible potential to seize the opportunity to eradicate cervical cancer within our lifetime.

London Health Sciences Centre (LHSC) and St. Joseph’s Heath Care London (St. Joseph’s) are celebrating the installation of a Total Laboratory Automation (TLA) system within the clinical microbiology laboratory.

The program led by 19 to Zero aims to support point-of-care testing needs beyond COVID-19 for urban and rural communities in Alberta through education and diagnosis at clinics.

BD announced that it had received Authorization under the Interim Order from Health Canada for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus (RSV) to help combat a potential “tripledemic” in the upcoming respiratory virus season.